North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 1.110

-0.9%

Jan 23 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (362)	5/12/1998 12:16:00 PM
From: Don W Stone	Read Replies (1) of 507

cacaito: Thanks for sharing your thoughts on your recent attendence at the Society of Pediatrics annuial meeting. You asked: << Don, What are the chances that other companies will quickly follow NVX strategy: MONOCOMPONENT toxoid vaccine? Is NVX protected by any patent? >>> Here is your answer as it is stated right from the NVX '97 annual report. " This vaccine technolgy was developed and patented at the National Institute of Child health and Human Development ( NICHD), and the world wide rights have been granted exclusively to North American Vaccine." I would say that it is not likely that any company will follow NVX's strategy . By the time they would have a product to market NVX will be marketing a multi combination vaccine DTaP-IPV-Hib-MenA,B,C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next